About Vascular Dynamics
Management
Ed Roschak
President & CEO
Ed
Ed Roschak
President & CEO
Ed joined Vascular Dynamics in November of 2017 as President and CEO. Ed has a track record of success with more than 20 years in the medical device industry. Prior to VDI, Ed served as the CEO of NuVasive Specialized Orthopedics after he orchestrated the successful acquisition of his former company, Ellipse Technologies, Inc., where he was president and CEO. Prior to his seven years at Ellipse, Ed held senior leadership positions at Broncus Technologies which spun-out Ashmatx, which was acquired by Boston Scientific. Previously, Ed held engineering and management roles at Hewlett-Packard, Origin Medsystems and Krebs Engineers. Ed is a named inventor on 30 granted patents and numerous patent applications. He has also been published in the Journal of Thoracic Surgery. Ed holds a MBA from the University of Oregon Executive Program and a BS in mechanical engineering from the University of California, Santa Barbara.
Martin Rothman
Chief Medical Officer
Martin
Martin Rothman
Chief Medical Officer
Professor Martin T. Rothman joined Vascular Dynamics in January 2019. Prof. Rothman is a highly regarded pioneer in interventional cardiology as evidenced by his clinical practice, his extensive pre-clinical and clinical research, and his success within the biotech industry having founded several start-ups and recently had leadership roles of increasing responsibilities at Medtronic.
Over thirty one years as a clinician at Bart’s Health in London, Prof. Rothman played a leading role in establishing interventional cardiology, particularly coronary angioplasty and stent implants. He helped found and became President of the professional society responsible for coronary intervention in the UK, The British Cardiovascular Intervention Society (BCIS). Prof. Rothman has been integral to clinical practice changes establishing new patient pathways for heart attack victims, rapid access for patients with unstable angina, and day-case coronary intervention, all of which have gained national acceptance. He is also widely published with over 200 publications and is the author of several books on interventional cardiology.
Prof. Rothman has been a pre-clinical and clinical evaluator of many new interventional devices and has invented and patented a number of novel devices and is named on more than 120 patents. Prof. Rothman has founded and run a number of successful start-up companies and raised more than $1B in investment funding for early stage ventures.
Prior to joining VDI, Prof. Rothman was Chief Medical Officer and Vice President of Medical Affairs for the Coronary, RDN & Structural Heart Division at Medtronic where he was part of the day-to-day management of a $3.5B revenue business. He also was involved in evidence development strategies and guided new product development teams addressing a wide product spectrum including those for coronary and vascular disease, resistant hypertension, and minimally invasive and percutaneous mitral valve replacement and repair.
John McIntyre
Chief Operations Officer
John
John McIntyre
Chief Operating Officer
John joined the Vascular Dynamics team in February of 2018, bringing his experience in quality system design and maturation as well as his in-depth knowledge of the global regulatory landscape. John has more than 25 years of medical device industry experience, with nearly 15 years in leadership roles. John most recently served as Global Vice President of Regulatory, Quality and Clinical Affairs for NuVasive, following the acquisition of Ellipse Technologies where he served in that same role. Prior to joining Ellipse in 2010, John held leadership positions at Magellan Spine Technologies and Cardiogenesis Corp. John started his career at Edwards Lifesciences (formerly Baxter Healthcare) where he held positions in Research and Development and Regulatory Affairs. John holds a MS in Biomedical Engineering from the University of California, Davis and a BS in Bioengineering from the University of California, San Diego.
Barbara Niksch
Vice President, Clinical Affairs
Barb
Barbara Niksch
Vice President, Clinical Affairs
Barbara joined Vascular Dynamics in July 2018, bringing her 30 years of medical device industry experience in the areas of Clinical and Regulatory Affairs. Most recently she served as Executive Director, Clinical Development Ophthalmology at Allergan. Prior to Allergan, Barbara served as VP of Clinical & Regulatory Affairs for AqueSys, Inc., which was acquired by Allergan. Prior to AqueSys, Barbara served as VP of Regulatory, Quality and Clinical Affairs at Visiogen, Inc. (acquired by Abbott) and Glaukos Corporation. Barbara obtained her BS in Biology from the University of Nevada Reno and she has an MBA from National University. Barbara is a past president of the Orange County Regulatory Affairs (OCRA) discussion group and also served as the Ophthalmic Industry Representative on the FDA’s Ophthalmic Devices Advisory Panel.
Mike Lazinski
Chief Financial Officer
Mike
Mike Lazinski
Chief Financial Officer
Mike Lazinski has served as Chief Financial Officer since January 2023. Mike has more than 20 years of finance and operational experience in the medical device industry with both large-scale companies as well as emerging technology organizations. He most recently served as Senior Vice President of Finance & Accounting at Masimo Corporation, where he was responsible for corporate planning and analysis, global accounting, SEC reporting, and investor outreach. Mike previously held senior finance leadership roles at NuVasive and Ellipse Technologies. Mike began his career in the Financial Management Program at GE Healthcare, where he then continued into successive finance and operational roles within several GE Healthcare businesses. Mike holds a BBA in Finance and Business Economics from the University of Notre Dame.
Board of Directors
Michael Henson
Chairman
Michael
Michael Henson
Chairman
Mr. Henson has founded or served as CEO and chairman/board member for 18 emerging healthcare (medical device or biotechnology) firms. Seven of these were privately held firms acquired by multinational companies, while six have advanced through the initial public offering (IPO) stage. Ten of the firms founded by Mr. Henson have been acquired by major healthcare firms. Several of these companies remain closely held private firms. In total, these firms have received financial investments of approximately $1 billion and have employed in excess of 1,000 people. Mr. Henson also serves as a principal manager for four private investment funds and as an advisor to two additional private investment funds, all focused on early and mid – stage medical device startup ventures.
Ilan Neugarten
Ilan
Ilan Neugarten
Mr. Neugarten has over 35 years of senior managerial experience, and over 15 years of experience in the medical industry. He brings to Rainbow Medical significant experience in medical devices venture capital investments, commercialization, and asset realization. Mr. Neugarten joined the Viola Partners Group in 2000 as a partner of DOR Ventures, a VC fund focusing on imaging technologies. During his period at DOR Ventures he led various investments including medical imaging ventures. Since 2006, he led the healthcare investments of Viola Partners. Prior to joining the Viola Partners Group, he worked for Scitex (NASDAQ:SCIX) in various management positions in Europe, Japan, and Israel. He received his BSc in Electronics from the Technion, Haifa Israel, and an MBA from Boston University.
Dr. Thomas Thaler
Thaler
Dr. Thomas Thaler
Dr. Thaler has more than 15 years of experience in investment management and financial research. He is a former senior equity analyst at Bank Julius Baer covering medical technology and healthcare service companies. He also has 15 years of experience in the biotech and medical technology industry holding senior management positions with Sulzer Medica, Schneider (Europe) and Boston Scientific. Dr. Thaler holds a MSc from the Swiss Federal Institute of Technology, (ETH) Zurich in Biochemistry, a PhD in life sciences and a Masters degree in Business Administration (ETH/BWI). Dr. Thaler is a board member of Vascular Dynamics, Ellipse Technologies, Interventional Spine, MiCardia, Tensys Medical and ValCare Medical.
Gary Burbach
Gary
Gary Burbach
Mr. Burbach has extensive experience in the medical technology industry. Prior to joining VDI, he served as CEO of Thoratec Corporation, a publicly-traded company that develops, manufactures and markets proprietary medical devices used for circulatory support. He has also served in executive roles at Digirad Corporation, where he also served on the board, Bacchus Vascular, Inc., a developer of catheter-based medical devices and Philips Nuclear Medicine, a division of Philips Electronics, which had also acquired ADAC Laboratories, where he served as president. He also serves on several boards of directors, including Fluidigm, Inc., Procyrion and Autonomic Technologies.Prior to his in-house management roles, Mr. Burbach spent six years with the management consulting firm of McKinsey & Company, Inc., where he was a senior engagement manager in the firm’s healthcare practice.Mr. Burbach has a B.S. in Industrial Engineering from Stanford University and an M.B.A. from Harvard Business School.
Stan Rabinovich
Stan
Stan Rabinovich
Mr. Rabinovich has over 40 years experience in medical device development and commercialization. Prior to joining VDI, Mr. Rabinovich served as Vice President of Advanced Technology and Discovery at Edwards Lifesciences until July 2020, focusing on technologies, applications, and business alliances related to structural heart disease. In 2001, Mr. Rabinovich co-founded Percutaneous Valve Technologies, Inc. (PVT), and as Executive Vice President, COO and Board member, led its development of transcatheter heart valves before being acquired by Edwards in 2004. Mr. Rabinovich also served as Corporate Director of Business Development for Datascope Corporation after having worked at Johnson and Johnson for 17 years in medical device development in Engineering, R&D, and Business Development roles. Mr. Rabinovich has an MS degree in Electrical Engineering from Riga Polytechnic Institute, and he was awarded the Phoenix Innovator’s Award at the 25th Annual Phoenix Medical Device Conference in 2018.
About Vascular Dynamics
Vascular Dynamics is developing an innovative, endovascular platform technology to offer compelling treatment options for patients at risk of life-threatening conditions underserved by conventional treatments.
The company’s MobiusHD technology features the first endovascular device to use the body’s natural baroreflex mechanism to modulate the autonomic nervous system. The endovascular baroreflex amplification (EVBA) approach targets both afferent and efferent neural pathways to realize a reduction in sympathetic tone and an increase in parasympathetic activity.
Clinical evaluations of this unique baroreflex modulation therapy for heart failure and high-risk hypertensive patients are in progress.
